Inkodess Continuous (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

The formulation contains drospirenone, a synthetic progestogen that suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, thereby preventing ovulation. Ethinylestradiol provides estrogenic support, stabilising the endometrium and enhancing cycle control, while both agents thicken cervical mucus to impede sperm passage.

The dosing regimen is determined by the prescribing healthcare professional. Typically, Inkodess Continuous is taken as one tablet daily at the same time each day, following the prescriber's instructions and the product’s package insert.

Inkodess Continuous is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, combined oral contraceptives are generally considered compatible with lactation, but the prescriber should evaluate individual risk‑benefit considerations.

To place an order, submit an enquiry on the Inkodess Continuous product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inkodess Continuous contains drospirenone, which has anti‑androgenic and antimineralocorticoid properties, potentially offering benefits such as reduced water retention and acne improvement compared with some other progestins. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives when taken correctly.

Store the tablets at ambient temperature below 25 °C, in the original blister pack or container, protected from moisture, heat and direct light. Do not store in bathrooms or near kitchen appliances. Keep out of reach of children.

Inkodess Continuous is taken orally, usually once daily at the same time each day. The tablet should be swallowed whole with water and not chewed or broken. Consistency in timing helps maintain contraceptive effectiveness.

The most serious risks include venous or arterial thromboembolism, such as deep‑vein thrombosis or pulmonary embolism, and severe hypertension. Women with a history of clotting disorders, smoking, or uncontrolled hypertension should be evaluated carefully before use.

Women with known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients, those with a history of thromboembolic disease, active liver disease, uncontrolled hypertension, or who are pregnant should avoid using Inkodess Continuous. Smoking women over 35 years of age are also advised against its use.